Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas

American Journal of Dermatopathology

Volumn 32, Issue 6, 2010, Pages 586-592

  Piris, Adriano ^a   Scopsi, Lucio ^b   Clemente, Claudio ^c   Cetti Serbelloni, Federica ^c   Mihm, Martin C ^a   Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Cancer Genetics Service   (Italy)

^c Anatomia Patologica   (Italy)

Author keywords

epidermal growth factor receptor; fluorescence in situ hybridization; hidradenocarcinoma; polysomy; trisomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DISOMY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HIDRADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SWEAT GLAND CARCINOMA; TRISOMY;

ACROSPIROMA; ADENOCARCINOMA; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SWEAT GLAND NEOPLASMS; TRISOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955174739     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181cd64f2     Document Type: Article

References (32)

1. Wong TY, Suster S, Nogita T, et al. Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients. Cancer. 1994;15: 1631-1643.
2. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006;33:726-730.
3. Berg J, McDivitt RW. Pathology of sweat gland carcinoma. Pathol Annu. 1968;3:123-144.
4. Keasbey LE, Hadley GG. Clear-cell hidradenoma: report of three cases with widespread metastases. Cancer. 1954;7:934-952.
5. Hernandez-Parez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma. A 10-year review. J Am Acad Dermatol. 1985;12: 15-20.
6. Headington JT, Niederhuber JE, Beals TF. Malignant clear cell acrospiroma. Cancer. 1978;41:641-647.
7. Santa Cruz DJ. Sweat gland carcinomas: a comprehensive review. Semin Diagn Pathol. 1987;4:38-74.
8. Kersting DW. Clear cell hidradenoma and hidradenocarcinoma. Arch Dermatol. 1963;87:323-333.
9. Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol. 1983;119:104-114.
10. Chung CK, Hefferman AH. Clear cell hidradenoma with metastasis: case report with a review of the literature. Plast Reconstr Surg. 1971;48: 177-179.
11. Nazarian RM, Kapur P, Rakheja D, et al. Atypical and malignant hidradenomas: a histologic and immunohistochemical study. Mod Pathol. 2009;22:600-610.
12. Kazakov DV, Ivan D, Kutzner H, et al. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation. Am J Dermatopathol. 2009;31:236-247.
13. Nash JW, Barrett TL, Kies M, et al. Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol. 2007;34: 49-54.
14. Battistella M, Mateus C, Lassau N, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol. 2009; [Epub ahead of print].
15. Jouary T, Kaiafa A, Lipinski P, et al. Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol. 2006;142:1366-1367.
16. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):9-15.
17. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
18. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005;23:6838-6845.
19. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655. (Pubitemid 40812628)
20. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
21. Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol. 2009;22:128-133.
22. Bell DW, Lunch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23: 8081-8092.
23. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer. 2007;109:1836-1844.
24. Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of EGFR amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest. 2004;84:582-587.
25. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA. 1992;89:4309-4313.
26. Mclnerney JM, Wilson MA, Strand KJ, et al. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem. 2001;80:538-549.
27. Buerger H, Packeisen J, Boecker A, et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol. 2004;203:545-550.
28. Kinoshta T, Takahashi Y, Sakashita T, et al. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim BiophysActa. 1999;1438:120-130.
29. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-293.
30. Dobashi Y, Takei N, Suzuki S, et al. Aberration of epidermal growth factor growth receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol. 2004;17:1497-1505.
31. Macarenco RS, Uphoff TS, Gilmer HF, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetics, and mutational analysis study. Mod Pathol. 2008;21:1168-1175.
32. Buckley AF, Burgart LJ, Sahai V et al. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129:245-251.